hotspot -WSS

hotspot

author：hotspot 2025-10-02 23:30:39 - browse：53

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Generate Biomedicines machine learning biotech raises $273M

hotspot

WSS

FDA approves updated Covid vaccines

New Covid vaccine is recommended for everyone 6 months or older

With competition flaring, obesity drug hits goal in liver disease study

R1 RCM gets $5.8 billion buyout offer from private equity firm

Private equity could exacerbate cardiology's overuse problem, experts fear

Long Covid needs a new name — and a new frame

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

How housing is health care on Long Island

Malaria cases in Florida and Texas: Here’s what you need to know

New documents shed light on MD Anderson Cancer Institute feud

Sports medicine is finally prioritizing gender equality

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Popular nasal decongestant doesn't actually relieve congestion

In age of alternative facts, a scholarly course on calling out crap

WATCH: Why do bright lights make us see spots?

entertainment

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Generate Biomedicines machine learning biotech raises $273M

Alabama frozen embryo ruling has major implications for IVF clinics

FDA approves updated Covid vaccines

Telehealth for opioid use disorder is lifesaving

Popular nasal decongestant doesn't actually relieve congestion

hotspot

entertainment

hotspot

focus